Watch for the Anticoagulant Bevyxxa During Transitions of Care

You may see some patients get Bevyxxa (beh-VYKE-sah, betrixaban), a new direct oral anticoagulant (DOAC), after hospital discharge.

We know extending VTE prophylaxis after discharge is helpful for certain high-risk surgical patients...such as after hip or knee surgery.

But Bevyxxa is only for "extended-duration" PREVENTION of venous thromboembolism (VTE) in nonsurgical patients with multiple risk factors...such as reduced mobility plus older age and heart failure.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote